The reason for the thumbs down is that it is old news and bad news with no relevance to STXS in the future.
Here are two articles which indicate that the MS cure via surgery is debunked.
Since 2009 over 30,000 MS patients have sought venoplasty to treat their disease. With the Buffalo study, however, that trend may soon subside. In the video below, Dr. Siddiqui (very, very clearly) points out that the study “isn’t the last word,” on CCSVI, but “the first word.” What's unfortunate is that this "first word" didn't come sooner, before tens of thousand of patients had sought treatment and millions of dollars had gone to questionable research. But this is what happens when it's not just the patients who are overcome with wishful thinking.
That foundation has now gotten a lot shakier. At this year’s Annual American Academy of Neurology Meeting in San Diego, researchers presented findings of a study designed to evaluate the treatment used by Zamboni and others to treat CCSVI. Their neck venoplasty – freeing up blood flow by inflating balloons in veins coming from the brain – was shown to not only be ineffective in treating MS, the procedure actually made matters worse.
The new study compared the outcomes of nine patients who had undergone Zamboni’s treatment with ten who’d received sham surgeries. Six months after the procedure, the patients receiving the neck venoplasty were worse off – while only one of the sham patients relapsed, four of the patients receiving the treatment had relapsed by follow-up. Furthermore, brain scans showed that whether or not patients received the treatment surgery or the sham did not affect the size or number of MS lesions in the nervous system.
The study, led by Adnan Siddiqui and Robert Zivadinov, both at the University of Buffalo’s School of Medicine and Biomedical Sciences, is admittedly a small one. Nonetheless, it is the first double-blind trial of the procedure. And, considering the dubious evidence that chronic cerebrospinal venous insufficiency causes MS in the first place, it is being taken as a fatal blow to a treatment that experts the world over feel should have been shut down before it was begun.
That''s what I am concerned about, where's the backlog, where's the future orders?
Yes, 5 would be nice although I would like to see some positive earnings before betting that high. I foolishly purchased 1000 shares above 4 years ago thinking that STXS was about to sell equipment to perform millions of procedures in the coming year. I'm still waiting and hoping for the best.
Insiders and 5% owners only own 13% of the stock.
Shares Held by Institutional & Mutual Fund Owners: 25%
Shares Held by Institutional & Mutual Fund Owners: 29%
There is a strong possibility that Apple could just buy this company and then charge Samsung, LG et. al. licensing fees paying it back for it's purchase price.
Why can't Apple just buy VHC on the open market. The current market cap is $250 million. The debt owed is $600 million with continuing legal fees and possible increased damages plus licensing fees. Apple should just buy the company. I bet it could scoop up all the shares for under $10/share. I'd sell.
I sold 5375 shares between 9.12 and 9.15 last week. I anticipate HIMAX back in the 6 to 7 range within a few months providing good dividends as well. That's when I will buy back in. I held for my position from 6 months to 1.3 years to make $12k. I do not anticipate future earnings surprises from HIMX after more than a decade of following this company. That's a Hold for long term based on purchasing the stock at the right price, not up here.
Taiwanese tech companies are not sold very often. They tend to stay in a family operation. I don't see HIMX being bought out. It's not like SNDK. It doesn't have great growth. It does pay a nice dividend. I trade this stock with the $6 to $9 range. That maybe all it's worth. I am a buyer when and if it declines in value again as has been it's long term trading pattern (minus Google Glass period).
Yes, but I sold today at 9.15 after holding only a few months from 6.09 (4000 shares). The light volume and lack of inertia whenever it goes near 9 for the past two years is a strong trading pattern. Lacking another Google Glass type impetus, I see HIMX dropping down again with shorts doing their damage to the price.
What I said was I'd sell for $50/share in THIS MARKET. By 2021, who knows. Just like my OPK and EXAS, I'm long and expect huge gains when their drugs/tests become the primary and universal standards for treatment/testing.
Sentiment: Strong Buy
I'd sell for $50 a share in this market. What if their current drugs treat migraines better than anything else? This would be a huge success for patients and shareholders. I'm holding my 5000 shares long as I've stated before. The current price is ridiculously low but I have too much biopharma and biotech right now, with all of it down. Wait until the sector gets hot again. SUPN should be close to $25 by year's end.
Sentiment: Strong Buy